Abstract: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.

Abstract: The present invention provides a composition of homogeneously glycosylated GM-CSF or a homogeneously glycosylated fragment thereof, wherein each molecule of GM-CSF or fragment thereof has the same glycosylation pattern, and for a given glycosylation site each molecule of GM-CSF or fragment thereof has the same glycan. The present invention further provides methods of making and using such compositions.

Abstract: Conjugates for the efficient delivery of sequence-specific antisense to cells of a selected type for the inhibition of a target protein have the general formula: peptide-HBL-antisense in which the peptide is a homing peptide which directs the conjugate to cells of a particular type, antisense is an antisense oligonucleotide having a sequence selected to provide sequence-specific inhibition of the target protein, and HBL is a heterobifunctional linker having reactivity towards amino and sulfhydryl groups.

Abstract: The disclosure relates to Compounds of Formulae (IA) and (IB): and pharmaceutically acceptable salts thereof wherein Z1, Z2, Z3, Xa, Xb, Xc, Xd, Y, X2, and X4 are as defined herein, compositions comprising an effective amount of a Compound of Formula (IA) and/or (IB), and methods to treat or prevent a condition, such cancer which overexpresses Her-kinases, comprising administering to an patient in need thereof a therapeutically effective amount of a Compound of Formula (IA) or (IB). The disclosure further relates to compounds of Formulae (IA) and IB) in which X2 is a leaving for introducing a radiolabeled atom, such as 124I or 131I and to methods of using such compounds in the preparation of radiolabeled compounds, particularly for use in imaging.

Abstract: The present application provides compounds useful in the inhibition of Hsp90, and hence in the treatment of disease.

Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.

Abstract: A chemical compound has the general formula: Ex4-linker-Sar(64Cu)-Fl in which Ex4 is an extendin-4 analog; linker is a polyethylene glycol (PEG) chain, for example formed with four ethylene glycol residues; Fl is a photoluminescent moiety, and Sar(64Cu) is an atom of copper-64 chelated in a sarcophagine moiety is useful as a multimodality imaging agent for detection and localization of insulinoma cells and ?-cell masses.

Abstract: The present invention discloses methods for treating non-malignant cell diseases by administering to an individual a construct comprising actinium-225 or bismuth-213 and an antigen of a non-malignant cell. Also, provided is a method for treating a solid tumor associated with an abnormal proliferation of cells by targeting an antigen of the tumor-associated vasculature with the constructs.

Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B): or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

Abstract: Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structure and are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.

Abstract: This invention provides mutated WT1 peptides SGQAYMFPNAPYLPSCLES (SEQ ID No:41) and QAYMFPNAPYLPSCL (SEQ ID No:42), immunogenic compositions and vaccines comprising same, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising same.

Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.

Abstract: Apparatus and methods are presented herein that permit real-time, accurate detection of residual tumor in the operating room. The Raman-based wide-field imaging apparatus and methods described herein permit real-time imaging of tumor-targeted R-MR nanoparticles over a wide field.

Abstract: This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.

Abstract: The present invention is related to complementarity determining region (CDR)-grafted humanized R24 antibodies that bind to the GD3 ganglioside antigen. The humanized antibodies disclosed herein have characteristics that are comparable or superior to the murine R24 antibody, and the humanized antibodies are useful in treating cancer (e.g. Melanoma).

Abstract: An ocular prosthesis includes a display device visible at an anterior portion of the ocular prosthesis. The display device is configured to present a changeable image that represents a natural appearance and movement for a visible portion of an eyeball of a subject. A system includes, besides the ocular prosthesis, an implant marker configured to move with an orbital implant disposed in an eye socket of a subject. A method includes determining a change in orientation of an orbital implant in a subject and determining an update to a natural appearance for a visible portion of an eyeball for the subject based on the change in orientation of the orbital implant. The method also includes rendering an update to an image of the natural appearance for a display device disposed in an ocular prosthesis configured to be inserted in the subject anterior to the orbital implant.

Abstract: The invention provides compounds, methods, pharmaceutical compositions, and kits for the treatment of proliferative disorders such as cancer. In one aspect, the methods comprise compounds that inhibit the activity of protein kinases, such as cell division cycle (Cdc) kinase. In another aspect, the methods comprise compounds that inhibit Cdc7 and/or Dbf4 activity. In another aspect, the methods comprise compounds that exhibit anti-proliferative properties useful in treating diseases such as cancer. Compounds useful for any of the methods include compounds of the Formula (A) or (B) or pharmaceutically acceptable salts thereof. Exemplary compounds of Formula (A) or (B) include granaticin A, granaticin B, dihydrogranaticin A, dihydrogranaticin B, medermycin, and actinorhodin.

Abstract: One embodiment of techniques for confocal microscopy includes illuminating a spot on a surface of a biological sample. A first emission intensity from the spot is detected in a first range of optical properties; and a second emission intensity in a second range. A pixel that corresponds to the spot is colored using a linear combination of the first and second emission intensities. Sometimes, the pixel is colored to approximate a color produced by histology. In some embodiments, a surface of a sample is contacted with a solution of acridine orange. Then, a spot is illuminated with a laser beam of wavelength about 488 nanometers (nm). Fluorescence emission intensity is detected above about 500 nm. Sometimes, a certain illumination correction is applied. In some embodiments, a sample holder that compresses a sample is removable from a stage that is fixed with respect to a focal plane of the microscope.

Abstract: The present invention provides pluripotent and multipotent stem cells, including embryonic stem cells, induced pluri-potent stem cells, adult stem cells and other progenitor cells, that have been modified to contain an inducible cancer-specific suicide gene construct that, upon induction, selectively kills stem- or progenitor-cell-derived cancerous cells without significant effect on healthy tissues or other (noncancerous) cells derived from such cells. This suicide gene construct expresses a dominant negative MYC-interfering protein (D-MIP) that acts as a tumor suppressor in cancer cells without significant deleterious effects on healthy cells and tissues. The suicide gene construct can also be used in gene therapies that produce cancers arising in association with the presence of the gene therapy vector and likewise discriminates between killing of cancerous cells and non-cancerous cells modified with a gene therapy vector.

Abstract: This invention provides a polyvalent vaccine comprising at least two conjugated antigens selected from a group containing glycolipid antigen, polysaccharide antigen, mucin antigen, glycosylated mucin antigen and an appropriate adjuvant. This invention also provides a multivalent vaccine comprising at least two of the following: glycosylated MUC-1-32mer, Globo H, GM2, Ley, Tn(c), sTN(c), and TF(c). This invention provides the vaccine above, wherein the adjuvant is saponin-based adjuvant. This invention provides a method for inducing immune response in a subject comprising administering an effective amount of the vaccine above to the subject. Finally, this invention provides a method for treating cancer in a subject comprising administering an appropriate amount of the vaccine above to the subject.